Ch 13: Blood. What does blood do? Transport: Regulation: Protection:

Size: px
Start display at page:

Download "Ch 13: Blood. What does blood do? Transport: Regulation: Protection:"

Transcription

1 Ch 13: Blood What does blood do? Transport: Regulation: Protection:

2 SLOs Describe the composition of plasma and list the major functions of plasma proteins. Map hematopoiesis, starting from a pluripotent hematopoietic stem cell. Distinguishing characteristics of each type of leukocyte. Define hematocrit, describe how a person s hematocrit is determined, and identify the clinical relevance of this value. Describe the molecular structure of hemoglobin and explain its function. Distinguish between the different types of anemias. Diagram the key steps of hemostasis, the coagulation cascade, and fibrinolysis.

3 Blood = connective tissue Extracellular matrix: Specialized cells: Average adult blood volume?

4 Fig 13.1

5 Function of plasma proteins?

6 Cellular Components of Blood - Overview 20-40% Total WBC: 4,000-11,000 Cellular Elements 2-8% 50-70% 1-4%

7 Blood Cells and Platelets Fig 13-3

8 Red Blood Cells Other name?

9 Hem(at)opoiesis = Blood Cell Formation Few uncommitted stem cells in red bone marrow throughout life time Controlled by, specifically CSFs and ILs

10 Stages of Erythropoiesis 2.5 million RBCs/sec Whole process takes 3 days Most iron recycled from old RBCs, rest from diet Transferrin =? Fig 13-4

11 Erythropoiesis EPO release Mitotic rate Tissue O 2 Maturation speed RBC bag of Hb for carrying O 2 lifespan ~ 120 days No aerobic respiration source of ATP? Tissue O 2 Reticulocytes enter circulation

12 RBC Production Regulated by Hormone synthesized by kidneys in response to hypoxemia due to anemia blood flow to kidneys declining O 2 content of air in lungs declining, due to disease or high altitude respiratory surfaces of the lungs damaged EPO gene cloned in 1985 Recombinant EPO now available

13 EPO Use in therapy (?) abuse in sport (?)

14 See Ch 16, page 559! Hemoglobin (Hb) Quaternary protein structure? Requires iron (Fe) HbA vs. HbF vs. HbS Reversible binding between Fe 2+ & O 2 Oxyhemoglobin vs. deoxyhemoglobin Carboxyhemoglobin CO: A toxic gas (Fitness Application p. 560)

15 RBC Disorders Polycythemia vera (PCV ~ 60-70%) Anemias (O 2 carrying capacity too ) Hemorrhagic anemia Fe deficiency anemia Hemolytic anemia, due to genetic diseases (e.g. Hereditary spherocytosis) or infections Pernicious anemia see p. 714 Renal anemia Aplastic anemia

16 Sickle Cell Anemia 1 st genetic illness traced to a specific mutation: DNA: CAC CTC aa: glutamic acid valine (aa #6 of 146) HbA HbS crystallizes under low oxygen conditions

17 Platelets = Thrombocytes Cytokine stimulating platelet production? Precursor cell in BM: ; polyploid Mechanism? ~ 4,000 platelets per cell Fig 16-7 live ~ 5-9 days Platelets contain granules filled with clotting proteins & cytokines (e.g.: serotonin) Activated when blood vessel wall damaged

18 Hemostasis = stops bleeding. Opposite of hemorrhage. Too little hemostasis Too much hemostasis Three major steps of hemostasis: 1. Vasoconstriction 2. Platelet plug (temporary blockage of hole) 3. Coagulation (clot formation seals hole until tissues repaired)

19 Steps of Hemostasis Vessel damage exposes collagen fibers Platelets adhere to collagen & release factors + feedback loop local vasoconstriction & platelet aggregation decreased blood flow platelet plug formation

20 Simultaneously: The Coagulation Cascade Fig 13-9 Cascade is complicated network! Numbering of coagulation factors according to time of discovery

21 Common Coagulation Pathway Intrinsic pathway Extrinsic pathway Active factor X Prothrombin thrombin fibrinogen fibrin reinforces platelet plug clot

22 Structure of Blood Clot Plasmin, trapped in clot, will dissolve clot by fibrinolysis SEM x 4625 Clot formation limited to area of injury: Intact endothelial cells release anticoagulants (heparin, antithrombin III, protein C).

23 Clot Busters & Anticoagulants Dissolve inappropriate clots Enhance fibrinolysis Examples: Urokinase, Streptokinase & t-pa Prevent coagulation by blocking one or more steps in fibrin forming cascade Inhibit platelet adhesion plug prevention Examples:

24 Hemophilia A

25 Hemophilia A (Factor VIII Deficiency)

Physiology Unit 3 HEMATOLOGY

Physiology Unit 3 HEMATOLOGY Physiology Unit 3 HEMATOLOGY In Physiology Today Hematocrit Percentage of blood volume that is erythrocytes 45% in men 42% in women Average blood volume in is 5 L Plasma Large amounts of organic/inorganic

More information

Veins Valves prevent engorgement and backflow. Baroreceptor reflex. Veins returning blood

Veins Valves prevent engorgement and backflow. Baroreceptor reflex. Veins returning blood Veins have large radii and low resistance. Walls are thin, not elastic Most blood volume is in veins Veins returning blood Veins Valves prevent engorgement and backflow Sympathetic NS constricts veins

More information

Chapter 19b Blood, cont d

Chapter 19b Blood, cont d Chapter 19b Blood, cont d White Blood Cells WBCs account for less than 1% of blood volume. There are two major histological categories of WBCs the granulocytes and the agranulocytes. GRANULOCYTES are Basophils,

More information

Overview of Anatomy and Physioloy II Second Year Students

Overview of Anatomy and Physioloy II Second Year Students University of Baghdad College of Nursing Department of Basic Medical Sciences Overview of Anatomy and Physioloy II Second Year Students Asaad Ismail Ahmad, Ph.D. Asaad Ismail Ahmad, Ph.D. Electrolyte and

More information

These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides.

These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides. These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides. If you would like the 1 slide per page handouts, please ask

More information

Sign up to receive ATOTW weekly -

Sign up to receive ATOTW weekly - BLOOD PHYSIOLOGY PART 2 ANAESTHESIA TUTORIAL OF THE WEEK 231 11 TH JULY 2011 Dr Karen Hayes Royal Devon & Exeter Correspondence to: kmhayes@hotmail.co.uk QUESTIONS Before continuing, try to answer the

More information

LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY

LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY 1 WHEN IS THE LAB REQUIRED TO INVESTIGATE FOR A POSSIBLE BLEEDING DISORDER? Clinically suspected bleeding tendency

More information

Blood is 55% Plasma (Liquid)

Blood is 55% Plasma (Liquid) Blood is 55% Plasma (Liquid) The plasma portion of blood is: 91% Water Maintains blood volume Transports molecules 7% Proteins (ie: clotting proteins, albumin, immunoglobulins ) 2 % Salts, gases (O 2,

More information

Introduction Hemostasis: Tourniquet Test & Bleeding Time. Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO

Introduction Hemostasis: Tourniquet Test & Bleeding Time. Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO Introduction Hemostasis: Tourniquet Test & Bleeding Time Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO Hemostasis A series of reactions that function to stop bleeding, maintaining

More information

Upon completion of the Clinical Hematology rotation, the MLS student will be able to:

Upon completion of the Clinical Hematology rotation, the MLS student will be able to: Clinical Performance Objectives in Clinical Hematology Department of Medical and Research Technology University of Maryland School of Medicine Spring 2015 Upon completion of the Clinical Hematology rotation,

More information

Laboratory investigation in the Bleeding Patient. Dr Craig Taylor Consultant Haematologist May 2016

Laboratory investigation in the Bleeding Patient. Dr Craig Taylor Consultant Haematologist May 2016 Laboratory investigation in the Bleeding Patient Dr Craig Taylor Consultant Haematologist May 2016 Introduction Bleeding is common May consume significant resources Crossmatched blood Lab results may be

More information

Coagulation in perspective: Blood management. Objectives

Coagulation in perspective: Blood management. Objectives Coagulation in perspective: Blood management Julie Wegner, PhD jawrbl@gmail.com Objectives To gain a basic understanding of the following: 1. Coagulation components and processes Why patients bleed. 2.

More information

BLOOD COAGULATION. 1. The initial phase of the process is vascular constriction. This limits the flow of blood to the area of injury.

BLOOD COAGULATION. 1. The initial phase of the process is vascular constriction. This limits the flow of blood to the area of injury. BLOOD COAGULATION The ability of the body to control the flow of blood following vascular injury is paramount to continued survival. The process of blood clotting and then the subsequent dissolution of

More information

Session 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy

Session 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy ~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 1 of 4 Session 1 Topics Review of coagulation and the vascular phase of hemostasis Unfractionated heparin Low molecular

More information

Blood Product Utilization

Blood Product Utilization Who gets what & when Why not to give blood? Volume Expander For specific number (except as related to procedures) To patients with religious objections to blood transfusions Blood given only when necessary

More information

The Story of the Platelet Clump. Wayne Hall MTN Network Laboratory Magee-Womens Research Institute Pittsburgh, PA

The Story of the Platelet Clump. Wayne Hall MTN Network Laboratory Magee-Womens Research Institute Pittsburgh, PA The Story of the Platelet Clump Wayne Hall MTN Network Laboratory Magee-Womens Research Institute Pittsburgh, PA Reason for Alarm? Platelet Clumping was occurring in multiple African sites 1-2 times per

More information

Drugs used in Thromboembolic Disease. Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014

Drugs used in Thromboembolic Disease. Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014 Drugs used in Thromboembolic Disease Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014 Drugs used in Thromboembolic Disease Anticoagulants: Heparin. Oral anticoagulants.

More information

Haemostasis. The function of haemostasis is: to prevent blood loss from injured vessels. to stop bleeding. to prevent thrombosis

Haemostasis. The function of haemostasis is: to prevent blood loss from injured vessels. to stop bleeding. to prevent thrombosis Haemostasis Haemostasis The function of haemostasis is: to prevent blood loss from injured vessels to stop bleeding to prevent thrombosis Haemostasis blood endothelium basement membrane subendothelium

More information

Special Coagulation - APC Resistance. DiaPharma Group, Inc. Customer Service: Technical Support:

Special Coagulation - APC Resistance. DiaPharma Group, Inc. Customer Service: Technical Support: Special Coagulation - APC Resistance DiaPharma Group, Inc. Customer Service: 1.800.526.5224 Technical Support:1.800.447.3846 www.diapharma.com 1 Review of Hemostasis Overview Pathways of coagulation, anticoagulation,

More information

Hematology Emergencies: Problems with Platelets

Hematology Emergencies: Problems with Platelets Hematology Emergencies: Problems with Platelets Christian Cable, MD, FACP Associate Professor of Medicine Division of Hematology & Oncology Texas A&M HSC College of Medicine Scott & White Healthcare Fundamentals

More information

Methods of Biomaterials Testing. Special Biology: Blood & Vessel

Methods of Biomaterials Testing. Special Biology: Blood & Vessel Methods of Biomaterials Testing Special Biology: Blood & Vessel Blood Compatibility Mainly: Inhibition of blood clot formation Materials in Bloodflow Venous catheter Dialysis filter Dialysis shunt Heart

More information

DEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK

DEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK DEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK 11794-8205 COAGULATION COMPETENCY EVALUATION FORM STUDENT NAME:

More information

Quantitative And Spatial Optimization Of Therapeutic Fusion Proteins

Quantitative And Spatial Optimization Of Therapeutic Fusion Proteins Quantitative And Spatial Optimization Of Therapeutic Fusion Proteins Jeffrey Way, Ph.D. Senior Staff Scientist, Wyss Institute, HMS CEO, General Biologics, Inc. 1 Chimeric Activators Drug design and targeted

More information

*NCCT is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program, provider #122.

*NCCT is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program, provider #122. COURSE DESCRIPTION Have you ever wondered why the blood that a phlebotomist collects in a tube will form a clot unless certain chemicals are added to the tube in advance to prevent it? Have you ever wondered

More information

The Coagulation Workup In The Office Setting

The Coagulation Workup In The Office Setting CAA Conference alm Springs 2012 The Coagulation Workup In The Office Setting CAA Conference alm Springs, October 2012 Robert Miller, A-C Henoch-Schoenlein urpura 1 CAA Conference alm Springs 2012 2 CAA

More information

Activated Protein C Resistance vs Factor V Leiden assay: Which is the most cost effective?

Activated Protein C Resistance vs Factor V Leiden assay: Which is the most cost effective? Activated Protein C Resistance vs Factor V Leiden assay: Which is the most cost effective? Rajiv K. Pruthi, M.B.B.S Co-Director, Special Coagulation Laboratory & Director, Mayo Comprehensive Hemophilia

More information

Rheological and biochemical analyses on blood coagulation ~ Discovery of a new pathway under stagnant flow conditions ~

Rheological and biochemical analyses on blood coagulation ~ Discovery of a new pathway under stagnant flow conditions ~ Rheological and biochemical analyses on blood coagulation ~ Discovery of a new pathway under stagnant flow conditions ~ Computer and Information Division, RIKEN Hiroki Iwata Supramolecular Science Laboratory,

More information

THE SCIENCE OF PLATELET RICH PLASMA

THE SCIENCE OF PLATELET RICH PLASMA THE SCIENCE OF PLATELET RICH PLASMA Cheri A. Ong, MD FACS ONG INSTITUTE FOR PLASTIC SURGERY & HEALTH WHAT IS PRP BLOOD PLASMA 55% of the body s today body volume 45% blood cells:- Red blood cells, White

More information

Common Inherited Bleeding Disorders

Common Inherited Bleeding Disorders CAA 2015 Annual Conference Common Inherited Bleeding Disorders Bob Miller, A October 8, 2015 VWF has two jobs Loosely bound to protect FVIII and tether to site of injury All other coagulation factors also

More information

Lab Guide Hematology Section Lab Guide

Lab Guide Hematology Section Lab Guide Lab Guide 2018 Hematology Section Lab Guide Anti - Xa level Anti - Xa level One tube 2.7 ml citrated blood sample filled up to the mark on the tube label. (Light blue top tube, citrated 3.2%). Blood should

More information

Celluvative. Cellular Therapies Redefined. A portfolio of products and services brought to you by: Saving lives today. Improving life tomorrow.

Celluvative. Cellular Therapies Redefined. A portfolio of products and services brought to you by: Saving lives today. Improving life tomorrow. Cellular Therapies Redefined A portfolio of products and services brought to you by: Saving lives today. Improving life tomorrow. cell u va tive / sel-yoo-vā-tiv/ noun 1. a partnership between BloodCenter

More information

Molecular Analysis of Genes and Gene Products. BIT 220 Chapter 22

Molecular Analysis of Genes and Gene Products. BIT 220 Chapter 22 Molecular Analysis of Genes and Gene Products BIT 220 Chapter 22 Credit: Courtesy Susan Lanzendorf, Ph.D., Jones Institute for Reproductive Medicine/Eastern Virginia Medical School 2003 John Wiley and

More information

RegenACR. autologous cellular regeneration. RegenACR A-PRP treatment. collagen fibers. 1,2 texture and elasticity. 3 volume & strength.

RegenACR. autologous cellular regeneration. RegenACR A-PRP treatment. collagen fibers. 1,2 texture and elasticity. 3 volume & strength. RegenACR autologous cellular regeneration RegenACR A-PRP treatment collagen fibers. 1,2 texture and elasticity. 3 volume & strength. 4,5 WHAT IS A-PRP Autologous Platelet Rich Plasma Plasma contains many

More information

Section 8. To introduce the basic theory and principles of collecting blood for Intraoperative Cell Salvage (ICS)

Section 8. To introduce the basic theory and principles of collecting blood for Intraoperative Cell Salvage (ICS) Section 8 Practicalities Blood Collection Aim To introduce the basic theory and principles of collecting blood for Intraoperative Cell Salvage (ICS) Learning Outcomes To identify the equipment used for

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Evaluation of Medicines for Human Use London, 29 July 2004 CPMP/BPWG/1089/00 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE CLINICAL INVESTIGATION OF PLASMA

More information

Iron Deficiency Anemia

Iron Deficiency Anemia Diagnosis of Iron Deficiency Anemia Using the Abaxis VetScan HM2 Hematology System Contributing Authors: Mary Anna Thrall, BA, DVM, MS, DACVP; Barton Gillespie, BS, DVM Ross University School of Veterinary

More information

Mutations. What is a mutation? a mutation is a change in the sequence of bases in DNA mutations may result in the production of defective proteins

Mutations. What is a mutation? a mutation is a change in the sequence of bases in DNA mutations may result in the production of defective proteins Mutations What is a mutation? a mutation is a change in the sequence of bases in DNA mutations may result in the production of defective proteins Mutations What environmental factors may cause mutations

More information

Category Storage Shelf Life Additional Criteria

Category Storage Shelf Life Additional Criteria CE Update [blood banking/transfusion medicine] Blood Components for Hemostasis Jun Teruya, MD, DSc, and Glenn Ramsey, MD From the Department of Pathology, Northwestern University Medical School, Chicago.

More information

Page 1. Name: UNIT: GENETICS TOPIC: DNA, GENES, CHROMOSOMES AND PROTEIN SYNTHESIS

Page 1. Name: UNIT: GENETICS TOPIC: DNA, GENES, CHROMOSOMES AND PROTEIN SYNTHESIS Name: 2705-1 - Page 1 UNIT: GENETICS TOPIC: DNA, GENES, CHROMOSOMES AND PROTEIN SYNTHESIS 1) Which diagram best represents the relative locations of the structures in the key below? 1) 2) 3) 4) 2) Hereditary

More information

OERMATAN SULFATE: A NEW CONCEPT IN ANTITHROMBOTIC THERAPY

OERMATAN SULFATE: A NEW CONCEPT IN ANTITHROMBOTIC THERAPY OERMATAN SULFATE: A NEW CONCEPT IN ANTITHROMBOTIC THERAPY by JOANNE VAN RYN-McKENNA, B.Sc., M.Sc. A Thesis Submitted to the School of Graduate Studies in Partial Fulfilment of the Requirements for the

More information

Biology 100. ALE #10. From Gene to Protein and Biotechnology Practice Problems DNA

Biology 100. ALE #10. From Gene to Protein and Biotechnology Practice Problems DNA Biology 100 Instructor: K. Marr Name Lab Section Group No. Quarter ALE #10. From Gene to Protein and Biotechnology Practice Problems Answer the following questions neatly and fully in the spaces provided.

More information

Basic coagulation applications and case studies

Basic coagulation applications and case studies Basic coagulation applications and case studies Jing Jin Clinical laboratory Scientist (MLS, ASCP) - Coagulation/Hematology Stanford University Hospital and Clinics 1 Agenda Overview about 3 major phases

More information

Improving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm

Improving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm Improving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm Summer Syed (local PI) Keyvan Karkouti Deputy Anesthesiologist-in-Chief, Toronto General Hospital, University Health

More information

Chapter 3 The Immune System

Chapter 3 The Immune System Chapter 3 The Immune System Why is the Immune System Important? Why is the Immune System Relevant to HIV? T Lymphocyte Infected by HIV Brief History of Immunology Immunity- Observation reported in 430

More information

engineering microvasculature-on-chip models as research-enabling systems for hemostasis and thrombosis

engineering microvasculature-on-chip models as research-enabling systems for hemostasis and thrombosis engineering microvasculature-on-chip models as research-enabling systems for hemostasis and thrombosis Wilbur A. Lam, MD, PhD Associate Professor Wallace H. Coulter Department of Biomedical Engineering

More information

Chapter 10. Oxygen Transporting Proteins

Chapter 10. Oxygen Transporting Proteins Chapter 10 Oxygen Transporting Proteins Oxygen-transport proteins Vertebrates Myoglobin (Muscle) Hemoglobin (Blood) Invertebrates Hemerythrin Hemocyanin Heme Cu Cu O 22 Cu O 2 -binding site of hemocyanin

More information

Daily Agenda. Make Checklist: Think Time Replication, Transcription, and Translation Quiz Mutation Notes Download Gene Screen for ipad

Daily Agenda. Make Checklist: Think Time Replication, Transcription, and Translation Quiz Mutation Notes Download Gene Screen for ipad Daily Agenda Make Checklist: Think Time Replication, Transcription, and Translation Quiz Mutation Notes Download Gene Screen for ipad Genetic Engineering Students will be able to exemplify ways that introduce

More information

Discussion. Objectives:

Discussion. Objectives: EXERCISE 13: SPECIMEN PROCESSING Skills: 15 points Objectives: 1. Explain how a centrifuge works. 2. Name five types of centrifuges and tell what each is used for. 3. Safely and correctly demonstrate the

More information

The Combined Use of Bypassing Agents with Antithrombin Reduction in Plasma of Hemophilia A and B Patients with Inhibitors

The Combined Use of Bypassing Agents with Antithrombin Reduction in Plasma of Hemophilia A and B Patients with Inhibitors Venkat Living Venkat with Hemophilia Living with Hemophilia The Combined Use of Bypassing Agents with Antithrombin Reduction in Plasma of Hemophilia A and B Patients with Inhibitors Tami Livnat 1, Alfica

More information

Characteristics. Capable of dividing and renewing themselves for long periods of time (proliferation and renewal)

Characteristics. Capable of dividing and renewing themselves for long periods of time (proliferation and renewal) STEM CELLS (p 2-8) Overview The body is made up of about 200 different kinds of specialised cells, such as muscle cells, nerve cells, fat cells and skin cells. Cells with the capacity to give rise to the

More information

Disclosures. Thromboelastography. TEG Methodology. TEG Output. Thromboelastography (TEG): Basics & Clinical Applications

Disclosures. Thromboelastography. TEG Methodology. TEG Output. Thromboelastography (TEG): Basics & Clinical Applications Thromboelastography (TEG): Basics & Clinical Applications Paula J. Santrach MD Associate Professor, Laboratory Medicine Mayo Clinic Rochester, MN Disclosures Relevant financial relationships NONE Off label

More information

Apheresis Anticoagulant Removal. Oluwatoyosi Onwuemene, MD MS May 6th, 2017

Apheresis Anticoagulant Removal. Oluwatoyosi Onwuemene, MD MS May 6th, 2017 Apheresis Anticoagulant Removal Oluwatoyosi Onwuemene, MD MS May 6th, 2017 Talk Outline Case presentation Factors associated with drug removal TPE s effects on hematologic parameters Anticoagulant properties

More information

Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase

Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase Clinical Hemorheology and Microcirculation 23 (2000) 213 218 213 IOS Press Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase Lirong Jin

More information

The Power in You. TM

The Power in You. TM RegenKit THT Autologous Platelet Rich Plasma (A-PRP) The Power in You. TM Biologics Concentrated on Healing RegenKit THT Autologous Platelet Rich Plasma (A-PRP) The RegenKit THT is designed to be used

More information

EUKARYOTIC REGULATION C H A P T E R 1 3

EUKARYOTIC REGULATION C H A P T E R 1 3 EUKARYOTIC REGULATION C H A P T E R 1 3 EUKARYOTIC REGULATION Every cell in an organism contains a complete set of DNA. But it doesn t use all of the DNA it receives Each cell chooses different DNA sequences

More information

ASSAY METHODS FOR THE EXPLORATION OF FIBRINOLYSIS

ASSAY METHODS FOR THE EXPLORATION OF FIBRINOLYSIS ASSAY METHODS FOR THE EXPLORATION OF FIBRINOLYSIS Jean AMIRAL, President HYPHEN BioMed (France) Fibrinolysis Functions Neurology (brain) Fertility Cell Remodelling FIBRINOLYSIS Malignancy (metastasis)

More information

Arthrex Angel TM System. Indication-specific PRP and PRF gel preparations

Arthrex Angel TM System. Indication-specific PRP and PRF gel preparations Arthrex Angel TM System Indication-specific PRP and PRF gel preparations Arthrex Angel TM System The Arthrex Angel TM System is a revolutionary production system for platelet-rich plasma (PRP) formulations

More information

Pros and Cons of Gene Therapy in ß-Thalassemia

Pros and Cons of Gene Therapy in ß-Thalassemia Pros and Cons of Gene Therapy in ß-Thalassemia ß-Thalassemia: established and potential new therapeutic approaches Many ß-thalassemic patients are treated with blood transfusion and iron chelation. However,

More information

Platelet transfusion therapy. Orieji Illoh, M.D. January 23, 2007

Platelet transfusion therapy. Orieji Illoh, M.D. January 23, 2007 Platelet transfusion therapy Orieji Illoh, M.D. January 23, 2007 The Eighteenth Century Transfusions were done only sporadically, and were generally animal to human. Transfusion was generally thought of

More information

Dr. Suzana Voiculescu

Dr. Suzana Voiculescu Dr. Suzana Voiculescu Overview of hemostasis Initiated when trauma, surgery or disease disrupts the vascular endothelium, exposing blood to the subendothelial connective tissue Achieved by: 1)Vasconstriction

More information

Surgical Adhesives in Facial Plastic Surgery

Surgical Adhesives in Facial Plastic Surgery Surgical Adhesives in Facial Plastic Surgery Dean M. Toriumi, Victor K. Chung, Quintin M. Cappelle University of Illinois at Chicago Chicago, IL Supplement to Toriumi DM, Chung VK, Cappelle QM. Surgical

More information

Serine Proteases and their Inhibitors

Serine Proteases and their Inhibitors ugo Kubinyi, www.kubinyi.de Serine Proteases and their Inhibitors ugo Kubinyi Germany E-Mail kubinyi@t-online.de omepage www.kubinyi.de ugo Kubinyi, www.kubinyi.de Serine Proteases of Physiological Importance

More information

2013 W. H. Freeman and Company. 5 Function of Globular Proteins

2013 W. H. Freeman and Company. 5 Function of Globular Proteins 2013 W. H. Freeman and Company 5 Function of Globular Proteins CHAPTER 5: Function of Globular Proteins Key topics in protein function: Reversible binding of ligands is essential Specificity of ligands

More information

the tamoxifen treatment schedule used to induce recombination. Arrows indicate on which

the tamoxifen treatment schedule used to induce recombination. Arrows indicate on which SUPPLEMENTAL DATA Figure S1. Characterization of Vhl / mice. (A) Left panel shows a schematic outline of the tamoxifen treatment schedule used to induce recombination. Arrows indicate on which days tamoxifen

More information

Strategies for Assessment of Immunotoxicology in Preclinical Drug Development

Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Rebecca Brunette, PhD Scientist, Analytical Biology SNBL USA Preclinical Immunotoxicology The study of evaluating adverse effects

More information

Red Cell Transfusion LESSONS FROM TRAUMA

Red Cell Transfusion LESSONS FROM TRAUMA Red Cell Transfusion LESSONS FROM TRAUMA Sandro Rizoli, MD PhD FRCSC FACS Professor Surgery & Critical Care Medicine Trauma Program Director Chair Trauma Care Disclosure KCI Canada CSL Behring NovoNordisk

More information

Genetic Basis of Development & Biotechnologies

Genetic Basis of Development & Biotechnologies Genetic Basis of Development & Biotechnologies 1. Steps of embryonic development: cell division, morphogenesis, differentiation Totipotency and pluripotency 2. Plant cloning 3. Animal cloning Reproductive

More information

HEMOSTASIS IN SURGERY

HEMOSTASIS IN SURGERY Greco D.P.- M.D.-F.A.C.S. Director SSD Day Surgery Torino 25-27 november 2010 HEMOSTASIS IN SURGERY The normal physiological response that prevents significant blood loss following vascular injury is called

More information

Biological evaluation of medical devices. Part 4: Selection of tests for interactions with blood

Biological evaluation of medical devices. Part 4: Selection of tests for interactions with blood Provläsningsexemplar / Preview INTERNATIONAL STANDARD ISO 10993-4 Third edition 2017-04 Biological evaluation of medical devices Part 4: Selection of tests for interactions with blood Évaluation biologique

More information

Marcia L. Zucker, Ph.D. ZIVD LLC

Marcia L. Zucker, Ph.D. ZIVD LLC Marcia L. Zucker, Ph.D. ZIVD LLC 1 Explain why ACTs from different systems are not the same Develop a plan for switching from one ACT system to another Describe why ACT and aptt are not interchangeable

More information

ROTEM Basic Interpretation Guide

ROTEM Basic Interpretation Guide ROTEM Basic Interpretation Guide Parameter: Clotting Time CT - Clotting Time (seconds) The time from the start of the test until first significant levels of a clot are detected. This measurement is initiated

More information

Sysmex CS-2500 Hemostasis System Unrestricted Siemens Healthcare Diagnostics Inc All rights reserved.

Sysmex CS-2500 Hemostasis System Unrestricted Siemens Healthcare Diagnostics Inc All rights reserved. Excel with Confidence Sysmex CS-2500 Hemostasis System Unrestricted Siemens Healthcare Diagnostics Inc. 2015 All rights reserved. General Lab Challenges Test Volume Financial Performance Accuracy Reliability

More information

Residual Serum Thrombin

Residual Serum Thrombin Residual Serum Thrombin Activity Murray Weiner N RECENT YEARS a remarkable number of blood and tissue components have been found to play a role in the formation of thrombin, the enzyme ultimately responsible

More information

R.Li, C.Swaelens, F.Vandermijnsbrugge, B.Cantinieaux BSTH Laboratory of haematology, Porte de Hal,

R.Li, C.Swaelens, F.Vandermijnsbrugge, B.Cantinieaux BSTH Laboratory of haematology, Porte de Hal, Institut J. Bordet Normal with Actin-FS avoids intrinsic pathway factors assays in the presence of an isolated prolongation of (Platelin-LS) without hemorrhagic history R.Li, C.Swaelens, F.Vandermijnsbrugge,

More information

Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation

Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation Laboratory Investigation of Challenging Cases Laura A. Worfolk, Ph.D Scientific Director, Coagulation Disclosures Employee of Quest Diagnostics Case focus: Importance of knowing test limitation/interpretations

More information

Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation

Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation Laboratory Investigation of Challenging Cases Laura A. Worfolk, Ph.D Scientific Director, Coagulation Coagulation Cascade XII XIIa XI HMWK/Prekallikrein XIa VII Injury IX X IXa VIII Xa X TF TF/VIIa Prothrombin

More information

Marcia L. Zucker, Ph.D. ZIVD LLC

Marcia L. Zucker, Ph.D. ZIVD LLC Marcia L. Zucker, Ph.D. ZIVD LLC 1 Monitoring hemostasis Bleeding Clotting 2 Picture courtesy of Helena Laboratories 3 Extrinsic Pathway Monitor with ACT / aptt WARFARIN Monitor with PT Common Pathway

More information

Hematotoxin producing snakes in Thailand พญ.ม ชฌ มา รอดเช อ พญ.อ สร ย หาญอ ท ยร ศม

Hematotoxin producing snakes in Thailand พญ.ม ชฌ มา รอดเช อ พญ.อ สร ย หาญอ ท ยร ศม Hematotoxin producing snakes in Thailand พญ.ม ชฌ มา รอดเช อ พญ.อ สร ย หาญอ ท ยร ศม Hematotoxin producing snakes Pit vipers (Crotalinae) Malayan pit viper (Calloselasma rhodostoma) Green pit viper (Trimeresurus

More information

From DNA to Protein Structure and Function

From DNA to Protein Structure and Function STO-106 From DNA to Protein Structure and Function Teacher information Summary: Students model how information in the DNA base sequences is transcribed and translated to produce a protein molecule. They

More information

Higher Human Biology Unit 1: Human Cells Pupils Learning Outcomes

Higher Human Biology Unit 1: Human Cells Pupils Learning Outcomes Higher Human Biology Unit 1: Human Cells Pupils Learning Outcomes 1.1 Division and Differentiation in Human Cells I can state that cellular differentiation is the process by which a cell develops more

More information

CLOTTING FACTOR REPLACEMENT THERAPY

CLOTTING FACTOR REPLACEMENT THERAPY CLOTTING FACTOR REPLACEMENT THERAPY Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage

More information

Introduction. Principle

Introduction. Principle Contents Introduction............................................................ 2 Principle.............................................................. 2 Storage and Stability.....................................................

More information

Product Data Sheet - TRUEMAB

Product Data Sheet - TRUEMAB 888.267.4436 techsupport@origene.com www.origene.com Name:F13A1 (Factor XIIIa) mouse monoclonal antibody, clone OTI1H2 (formerly 1H2) Product Data Sheet - TRUEMAB Catalog: TA800305 Components: F13A1 (Factor

More information

Profibrinolytic diabody targeting PAI-1 and TAFI for treatment of acute thrombotic disorders

Profibrinolytic diabody targeting PAI-1 and TAFI for treatment of acute thrombotic disorders ProFiDIΛ Profibrinolytic diabody targeting PAI-1 and TAFI for treatment of acute thrombotic disorders THROMBOLYSIS WITH IMPROVED SAFETY A valorisation project of Unmet Medical Need = Safe Thrombolysis

More information

ANAT 3231 Cell Biology Lecture 21 Stem Cells

ANAT 3231 Cell Biology Lecture 21 Stem Cells ANAT 3231 Cell Biology Lecture 21 Stem Cells Outline What are Stem Cells? Totipotency - Pluripotency - Multipotency What are different sources of Stem Cells? Embryonic vs Adult Pros and Cons for each type

More information

SAMPLE H21-A5. January 2008

SAMPLE H21-A5. January 2008 January 2008 Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays; Approved Guideline Fifth Edition This document provides

More information

Clinical Policy: Humate-P (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404

Clinical Policy: Humate-P (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404 Clinical Policy: (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404 Effective Date: January 2008 Last Review Date: 12/16 See Important Reminder at the end of this

More information

Globins. The Backbone structure of Myoglobin 2. The Heme complex in myoglobin. Lecture 10/01/2009. Role of the Globin.

Globins. The Backbone structure of Myoglobin 2. The Heme complex in myoglobin. Lecture 10/01/2009. Role of the Globin. Globins Lecture 10/01/009 The Backbone structure of Myoglobin Myoglobin: 44 x 44 x 5 Å single subunit 153 amino acid residues 11 residues are in an a helix. Helices are named A, B, C, F. The heme pocket

More information

PRP Preparation. Simplicity for Success

PRP Preparation. Simplicity for Success PRP Preparation Simplicity for Success Features and Benefits of the Tropocells System Effectiveness Enables high platelet concentration by reducing the volume of plasma. Rapid and simple one step process

More information

Page 3. 18) The diagram below illustrates some key steps of a procedure in one area of biotechnology.

Page 3. 18) The diagram below illustrates some key steps of a procedure in one area of biotechnology. Name: 1117 1 Page 1 1) A small amount of DNA was taken from a fossil of a mammoth found frozen in glacial ice. Genetic technology can be used to produce a large quantity of identical DNA from this mammoth's

More information

Appendix B. Glossary of Acronyms and Terms

Appendix B. Glossary of Acronyms and Terms Appendix B. Glossary of Acronyms and Terms Glossary of Acronyms AABB ABC ABRA ACT ADP AHF AIDS ALT AMA AMS ARC ASCP ATIII ATP BTS CBC CCBC cdna CDC CFR CMV CPDA-1 CRC DBDR DHEW DHHS DNA DRG EBV EIA ELISA

More information

DNA & DNA Replication

DNA & DNA Replication DNA & DNA Replication DNA Structure How did Watson and Crick contribute to our understanding of genetics? Watson and Crick developed the double helix model for DNA DNA Structure What is a double helix?

More information

Murine TGFβ-antagonist (RAP-1332) Inhibits Fibrosis in a Murine Model of Myelofibrosis. Rajasekhar NVS Suragani, PhD

Murine TGFβ-antagonist (RAP-1332) Inhibits Fibrosis in a Murine Model of Myelofibrosis. Rajasekhar NVS Suragani, PhD Murine TGFβ-antagonist (RAP-1332) Inhibits Fibrosis in a Murine Model of Myelofibrosis Rajasekhar NVS Suragani, PhD Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF)

More information

AVOIDING ANTICOAGULATION in CRRT: An update on EMERGING MEMBRANES Available in 2012

AVOIDING ANTICOAGULATION in CRRT: An update on EMERGING MEMBRANES Available in 2012 AVOIDING ANTICOAGULATION in CRRT: An update on EMERGING MEMBRANES Available in 2012 1.-Rationale of Using Those Membranes 4.-Comparison with Other Strtegies 2.- When Should we Use Those? 5.- Remaining

More information